Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton kinase (BTK) inhibitor fenebrutinib, along with data ...

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later, ...

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...

Roche Holding AG (OTCQX:RHHBY, OTCPK:RHHVF, OTCQX:RHHBF) is a good long-term biotech to own. That's because it already has received FDA approval for its multiple sclerosis [MS] drug OCREVUS. This drug ...

Roche’s Phase III trial examining higher doses of intravenous (IV) Ocrevus (ocrelizumab) as a means of slowing disability progression in patients living with relapsing multiple sclerosis (MS) has not ...

– 77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years – – Initiation of Ocrevus ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the ...

Genentech is "bucking a trend" by charging less for its multiple sclerosis (MS) drug despite at least equal efficacy to others and improved safety, neurologist Michael Racke told BioWorld Today, ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...